Navigation Links
Relapse in Risk Management System Claims the Life of Robertson

This report mainly brings to the notice of the common man that how official failings led to a man being bludgeoned to death by a psychiatric patient// with a history of violence. Stuart Robertson was killed by James Smith, who was on conditional discharge from Leverndale Hospital in Glasgow, in October 2004. This report mainly gives us an insight of how there was no systematic approach to risk assessment.

There was a failure to respond adequately to clear signs that Smith's mental illness had relapsed while he was in the care of community-based mental health services. This report was by the Mental Welfare Commission for Scotland. It asks for a series of changes to be implemented by the Scottish Executive, NHS Greater Glasgow and social work chiefs in Glasgow. Smith, 46, had suffered mental problems since 1991. He was jailed for life in Glasgow in November after he admitted the homicide of Mr Robertson.

He had killed Mr Robertson, who also had a history of mental illness, by bludgeoning him to death with a hammer in Pollok Park, Glasgow. The report said that Smith's condition had relapsed in the summer of 2004 but there was no systematic approach to risk assessment in his care and supervision, and an inadequate focus by some of those involved in his care. There was no satisfactory strategy planned to deal with any relapse in his illness.

In the months before the killing he showed signs of relapse but was not recalled to hospital. The Executive, NHS Greater Glasgow and Glasgow City Council acknowledged it had identified weaknesses as the basic risk management was not proper. The deputy health minister, Lewis Macdonald, said that all steps to address the deficiencies identified are being done and the public need not worry about it.


'"/>




Page: 1

Related medicine news :

1. Medications to Prevent Relapse to Cocaine Use
2. Alcoholism Drug Fails To Prevent Drinking Relapses
3. Treatment For Prostate Cancer Relapse Linked To Marital Status
4. New Drug More Effective than Tamoxifen in Preventing Breast Cancer Relapse
5. Femara: The Wonder Drug to Prevent Relapse of Breast Cancer.
6. Rogue Mammary Stem Cells Could Hold Key To Breast Cancer Relapse
7. Hepatitis B Relapse In Cancer Chemotherapy Can Be Avoided By Antiviral Drug
8. Leftover Cancer Cells May Dictate Breast Cancer Relapse
9. Kids are More Prone to Tonsillitis Relapse
10. Colon Cancer Relapse Mainly Caused by Stem Cells
11. ALL Relapses in Most Children After Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: